Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00329238 · ClinicalTrials.gov registry record · Phase 3
Secondary Prevention of Venous Thrombo Embolism (VTE).
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,867
- Enrollment target
NCT00329238 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 2,867 participants.
The verdict
NCT00329238, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,867 participants
- Enrollment target
Study Summary
The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and secondary prevention of symptomatic venous thromboembolism in patients who have been successfully treated with standard doses of an approved anticoagulant for three to twelve months for confirmed acute symptomatic Venous Thrombo-embolism.
Interventions
- DRUG Warfarin
- DRUG Dabigatran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,867 participants |
| Start Date | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00329238
The ClinicalTrials.gov registry entry for NCT00329238 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,867 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Warfarin is the first listed.
NCT00329238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00329238 about?
NCT00329238 is a clinical study titled "Secondary Prevention of Venous Thrombo Embolism (VTE).". The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and secondary prevention of symptomatic venous thromboembolism in patients who have...
What is the current status of trial NCT00329238?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,867 participants. The study started on 2006-05.
What interventions are being tested in trial NCT00329238?
The interventions under investigation include: Warfarin (DRUG), Dabigatran (DRUG).
Who is sponsoring clinical trial NCT00329238?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.